Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.

ABSTRACT:

Background

Few data on the thromboembolic (TE) risk of paroxysmal and persistent atrial fibrillation (AF) are available. This study aimed to assess the incidence of TE events in paroxysmal and persistent AF.

Methods

We performed a subset post hoc analysis of 771 patients with paroxysmal and 463 with persistent AF enrolled in the multicenter, prospective, randomized, double-blind, placebo-controlled GISSI-AF trial - comparing the efficacy of valsartan versus placebo in preventing AF recurrences - where the choice of antithrombotic treatment was left to the judgment of the referring physician. TE and major outcome events were centrally validated. AF recurrences were detected by frequent clinic visits and a transtelephonic monitoring device with weekly and symptomatic transmiss

SUBMITTER: Disertori M 

PROVIDER: S-EPMC3639147 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature